Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
doi: https://doi.org/10.1101/2021.12.23.21267374

Article usage

Article usage: December 2021 to November 2023

AbstractFullPdf
Dec 2021492771707
Jan 202231924571101
Feb 202251543301733
Mar 20221332186572
Apr 2022625172338
May 2022803132404
Jun 2022651108688
Jul 202281882263
Aug 2022544112105
Sep 20225173852
Oct 202239047176
Nov 20222381932
Dec 20222991635
Jan 2023507625
Feb 20232321927
Mar 20231271522
Apr 20231711116
May 2023107419
Jun 2023144811
Jul 2023117915
Aug 2023871914
Sep 20231591326
Oct 202311832417
Nov 2023713689
Back to top
Posted December 25, 2021.
Download PDF
Data/Code
Email
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area